Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus

Arthritis Care and Research

Volumn 69, Issue 1, 2017, Pages 115-123

  Iaccarino, Luca ^a   Bettio, Silvano ^a   Reggia, Rossella ^b   Zen, Margherita ^a   Frassi, Micol ^b   Andreoli, Laura ^b   Gatto, Mariele ^a   Piantoni, Silvia ^b   Nalotto, Linda ^a   Franceschini, Franco ^b   Larosa, Maddalena ^a   Fredi, Micaela ^b   Punzi, Leonardo ^a   Tincani, Angela ^b   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGE; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DAS28; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL DISEASE ASSESSMENT; POLYARTHRITIS; PROSPECTIVE STUDY; PROTEINURIA; SKIN DISEASE; SKIN MANIFESTATION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; CLINICAL TRIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85004045242     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22971     Document Type: Article

References (44)

1. Zen M, Iaccarino L, Doria A, Canova M, Bettio S, Gatto M, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012;30:856–63.
2. Cervera R, Doria A, Amoura Z, Khamashta M, Schneider M, Guillemin F, et al. Patterns of systemic lupus erythematosus expression in Europe. Autoimmun Rev 2014;13:621–9.
3. Gatto M, Zen M, Ghirardello A, Bettio S, Bassi N, Iaccarino L, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013;12:523–6.
4. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006;119:700–6.
5. Iaccarino L, Bettio S, Zen M, Nalotto L, Gatto M, Ramonda R, et al. Premature coronary heart disease in SLE: can we prevent progression? Lupus 2013;22:1232–42.
6. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012;51:491–8.
7. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467–72.
8. Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37:1822–7.
9. Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117–22.
10. Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949–56.
11. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:1316–9.
12. Mak A, Isenberg D, Lau CS. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol 2013;9:301–10.
13. Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001;10:93–6.
14. Nived O, Jönsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002;29:1398–400.
15. Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61:1065–70.
16. Doria A, Iaccarino L, La Montagna G, Mathieu A, Piga M, Galeazzi M, et al. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. Clin Exp Rheumatol 2015;33:375–84.
17. Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014;73:154–60.
18. Doria A, Gatto M, Iaccarino L, Punzi L. Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus 2015;24:507–15.
19. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014;13:770–7.
20. Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014;12:30.
21. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.
22. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzovà D, et al. A phase III, randomized, placebo controlled study of belimumab, a monoclonal antibody that inhibits B lymphocytes stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
23. Specchia ML, de Waure C, Gualano MR, Doria A, Turchetti G, Pippo L, et al. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. Biomed Res Int 2014; 2014:704207.
24. Pierotti F, Palla I, Treur M, Pippo L, Turchetti G. Assessment of the economic impact of belimumab for the treatment of systemic lupus erythematosus in the Italian setting: a cost-effectiveness analysis. PLoS One 2015;10:e0140843.
25. Díaz-Cerezo S, García-Aparicio ÁM, Parrondo J, Vallejo-Aparicio LA. Cost-effectiveness analysis of belimumab in patients with systemic lupus erythematosus in Spain. Farm Hosp 2015;39:161–70.
26. Husein-ElAhmed H, Callejas-Rubio JL, Rios-Fernandez R, Ortego-Centeno N. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatol Venereol Leprol 2014;80:477–8.
27. Danve A, Perry L, Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report. Semin Arthritis Rheum 2014;44:195–7.
28. Jüptner M, Zeuner R, Schreiber S, Laudes M, Schröder JO. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. Lupus 2014;23:428–30.
29. Fließer EE, Korsten P, Koziolek MJ, Niewold TB, Patschan D, Müller GA, et al. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus 2013;22:1523–5.
30. Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, et al. Belimumab for the treatment of refractory systemic lupus erythematosus: real life experience of the first year of use in 18 Italian patients. Isr Med Assoc J 2014;16:651–3.
31. Scheinberg M, Golmia R. Real life experience on the effect of belimumab in patients with active systemic lupus. Springerplus 2014;3:758.
32. Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol 2015;42:2288–95.
33. Cortes J, Andreu JL, Calvo J, Garcia-Aparicio AM, Coronell CG, Diaz-Cerezo S. Evaluation of use of belimumab in clinical practice settings (OBSErve study) in Spain: health resource utilization and labour absenteeism [abstract]. Value Health 2014;17:A534.
34. Schwarting A, Koscielny VB, Carnarius H, Cholmakow-Bodechtel C, Alexander T, Fiehn C, et al. Outcomes in systemic lupus erythematous (SLE) patients treated with belimumab in clinical practice settings: results from the observe study in GERMANY [abstract]. Ann Rheum Dis 2014;73:78–9.
35. Collins CE, Dall'Era M, Kan H, Macahilig C, Molta C, Koscielny V, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 2016;3:e000118.
36. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfiled NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
37. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10:365–81.
38. Van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343–9.
39. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie L, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus, combined results from two phase III trials. Ann Rheum Dis 2012;71:1833–8.
40. Dooley MA, Houssiau F, Aranow C, D′ Cruz DP, Askanase A, Roth DA, et al, and the BLISS-52 and -76 Study Groups. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63–72.
41. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560–4.
42. Seguro LP, Rosario C, Shoenfeld Y. Long-term complications of past glucocorticoid use. Autoimmun Rev 2013;12:629–32.
43. Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 2016;25:699–709.
44. Wallace DJ, Navarra SV, Petri MA, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013;22:144–54.